Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vipoglanstat - Gesynta Pharma

Next Previous
Drug Profile

Vipoglanstat - Gesynta Pharma

Alternative Names: BI-1029539; GS-248; OX-MPI

Latest Information Update: 11 Nov 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biolipox
  • Developer Gesynta Pharma
  • Class Anti-inflammatories; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
  • Mechanism of Action Prostaglandin-E synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Systemic scleroderma

Most Recent Events

  • 08 Nov 2022 Gesynta Pharma has files patent protection for new compounds as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), in Denmark, Argentina, Slovenia, Singapore, Poland, Serbia, Mexico, South Korea, Taiwan, Georgia, Portugal, Israel, Chile, Morocco, Colombia, Croatia, Cyprus, San Marino.
  • 08 Nov 2022 Gesynta Pharma has patent protection for new compounds as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), in United States, Europe, China, Japan and several additional important markets which are expected to expire in August 2031 (3725858; Gesynta Pharma pipeline. November 2022).
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Systemic-scleroderma(In volunteers) in Sweden (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top